A proteomic approach to obesity and type 2 diabetes
Entity
UAM. Departamento de Pediatría; Instituto de Investigación del Hospital de La Princesa (IP)Publisher
John Wiley & Sons Ltd.; Foundation for Cellular and Molecular MedicineDate
2015-01-01Citation
10.1111/jcmm.12600
Journal of Cellular and Molecular Medicine 19.7 (2015): 1455-1470
ISSN
1582-1838; 1582-4934 (on line)DOI
10.1111/jcmm.12600Funded by
This work is funded by Ministerio de Ciencia e Innovación (BFU2011–27492), Fondos de Investigación Sanitaria (PI1302195), Centro de Investigación Biomédica en Red Fisiopatología de Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III and Fundación de Endocrinología y Nutrición. Dr. Elena López Villar is supported by ISCIII Spanish Health System (SNS BOE 2012) and she is Delegate of HUPO (Human Proteome Organization) supporting clinical proteomic studies at Hospital Niño Jesús of Madrid, Spain, to improve diagnosis and therapies via researchProject
Gobierno de España. BFU2011–27492Editor's Version
http://dx.doi.org/10.1111/jcmm.12600Subjects
Biomarkers; Diabetes mellitus type 2; Obesity; Proteomics; MedicinaRights
© 2015 The AuthorsAbstract
The incidence of obesity and type diabetes 2 has increased dramatically resulting in an increased interest in its biomedical relevance. However,
the mechanisms that trigger the development of diabetes type 2 in obese patients remain largely unknown. Scientific, clinical and pharmaceutical
communities are dedicating vast resources to unravel this issue by applying different omics tools. During the last decade, the advances in
proteomic approaches and the Human Proteome Organization have opened and are opening a new door that may be helpful in the identification
of patients at risk and to improve current therapies. Here, we briefly review some of the advances in our understanding of type 2 diabetes that
have occurred through the application of proteomics. We also review, in detail, the current improvements in proteomic methodologies and new
strategies that could be employed to further advance our understanding of this pathology. By applying these new proteomic advances, novel
therapeutic and/or diagnostic protein targets will be discovered in the obesity/Type 2 diabetes area
Files in this item
Google Scholar:López-Villar, Elena
-
Martos Moreno, Gabriel Ángel
-
Chowen, Julie Ann
-
Okada, Shigeru
-
Kopchick, John J.
-
Argente Oliver, Jesús
This item appears in the following Collection(s)
Related items
Showing items related by title, author, creator and subject.
-
Mutations in pregnancy-associated plasma protein A2 cause short stature due to low IGF-I availability
Dauber, Andrew; Muñoz-Calvo, María T.; Barrios, Vicente; Domené, Horacio M.; Kloverpris, Soren; Serra-Juhé, Clara; Desikan, Vardhini; Pozo Román, Jesús; Muzumdar, Radhika; Martos Moreno, Gabriel Ángel; Hawkins, Federico G.; Jasper, Héctor G.; Conover, Cheryl A.; Frystyk, Jan; Yakar, Shoshana; Hwa, Vivian; Chowen, Julie Ann; Oxvig, Claus; Rosenfeld, Ron G.; Pérez-Jurado, Luis A.; Argente Oliver, Jesús
2016-04-01